Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

Inclusion Criteria:

• Participants able to give voluntary informed consent before starting anystudy-related assessments or procedures (to be obtained/documented as per localregulations).

• Adults (≥18 years of age) at time of informed consent.

• Participants with at least 1-year history of migraine with or without auraconsistent with a diagnosis according to the ICHD-3 (2018).

• Participants with history of experiencing at least 3 migraine attacks per month withmoderate to severe symptoms

• Participants prescribed ubrogepant by investigator for the acute treatment ofmigraine according to local product label, independent of and prior to studyparticipation

• Participants willing and able to comply with the requirements of the study.

• Participants with access to an electronic device (mobile phone, tablet, laptop,etc.) with internet access.

Exclusion Criteria:

• Participants previously exposed to a ubrogepant or rimegepant as routine therapy orthrough a clinical trial.

• Participants with history of known contraindications to ubrogepant as per locallabeling.

• Participants Pregnant or planning to be pregnant or of childbearing potential notusing contraception

• Participants enrolled in any interventional studies that may include investigationalcompounds for migraine or non-AbbVie observational studies.

• History or current evidence of any condition that might interfere with their abilityto comply with the study requirements, in the opinion of the investigator.